Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PXT002331 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PXT002331 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PXT002331 | DRUG | - |
Inclusion Criteria: 1. Subjects will be; 1.1. males or females of non childbearing potential 1.2. For females, non childbearing potential is defined as follows: * permanently sterile following hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or confirmed tubal occlusion (not tubal...
PXT002331 is an investigational small molecule being developed for the treatment of Parkinson's Disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under study to evaluate its safety, tolerability, and pharmacokinetics in humans.
PXT002331 is being developed by cbdMD, Inc., a company publicly traded under the ticker symbol YCBD on the stock market. The company is conducting clinical research to evaluate this investigational drug candidate for Parkinson's Disease.
PXT002331 is in Phase 1 clinical development. A Phase 1 trial has been completed, which was a first-in-human study designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. The drug remains investigational and is not yet approved for any use.
PXT002331 has one completed clinical trial registered under NCT02639221. This was a Phase 1, double-blind, placebo-controlled, first-in-human study with single and multiple ascending oral doses, conducted in the United Kingdom with 64 healthy male and female subjects aged 18 years and older.
The specific molecular target of PXT002331 has not been disclosed in available clinical trial information. As a small molecule being studied for Parkinson's Disease, its mechanism of action is not publicly detailed, and further research is needed to understand how it may exert potential therapeutic effects.